Racura Oncology Ltd (ASX:RAC) has officially changed its name from Race Oncology, following shareholder approval at the 2025 AGM held on Monday, November 24, 2025.
The Australian Securities and Investments Commission (ASIC) recorded the new name with effect from December 5, 2025.
The ASX will reflect the new name from the start of trading on Wednesday, December 10, 2025, with the company’s ticker “RAC” staying the same.
Fully funded trial
The name change comes just a day after the company announced it was fully funded to support the HARNESS-1 Phase 1a/b trial of RC220 in combination with Tagrisso® (osimertinib) in non-small cell lung cancer.
Read more: $3.22M additional funding secures Race Oncology’s HARNESS-1 trial
Together with proceeds from the early conversion of the May 2026 $1.25 piggyback options, and a binding commitment from CEO Dr Daniel Tillett to convert his $1.25 options, the more than $3.22 million private placement to a group of supportive existing sophisticated shareholders, provides the capital required to conduct the HARNESS-1 study. With funding now in place, the Race board has approved commencement of the trial.
HARNESS-1 has already received approval from the Human Research Ethics Committee for St Vincent’s Hospital. Patient enrolment remains subject to final institutional approval and site activation by Monash Health, which is expected between late Q4 2025 and early Q1 2026.
The first patient is expected to be enrolled in early Q1 2026.
About Racura Oncology
Racura Oncology is a Phase 3 clinical biopharmaceutical company focused on developing cancer therapies.
Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, resulting in potent inhibition of the cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients and has a well-characterised safety profile. Recent discoveries by Racura have supported composition of matter intellectual property filings that provide for 20 years of patent protection over RCDS1.
The company is advancing a proprietary formulation of RCDS1 (RC220) to address unmet medical needs across multiple oncology indications. This includes Phase 3 clinical programs in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, with the aim of delivering both cardioprotection and enhanced anticancer activity for patients with solid tumours.
Racura Oncology collaborates with Astex, MD Anderson Cancer Center, Sheba City of Health, UNC School of Medicine, the University of Wollongong and the University of Newcastle. The company is also exploring partnerships, licence agreements or commercial merger and acquisition opportunities to accelerate access to RC220 for cancer patients globally.
Further information is available at www.racuraoncology.com.